Precision BioSciences announces that its first-in-class gene therapy Pbgene-Dmd for Duchenne muscular dystrophy (DMD) has received Investigational New Drug (IND) application approval from the U.S. Food and Drug Administration (FDA).
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Fourth attempt finally approved! Brookfield (BAM.US) acquires Australian pipeline products manufacturer RWC for $2.9 billion, a 32% premium
Brookfield Asset Management has agreed to acquire Reliance Worldwide Corp. in an all-cash deal, valuing the Australian plumbing products company at approximately 4.1 billion Australian dollars (about 2.9 billion US dollars).

Spot Gold Surpasses $4,300 per Ounce, Up 0.16% for the Day
Hyundai Mobis' Earnings Could Be Dragged Lower by Stronger Won -- Market Talk
Japan Capex Outlook Solid on AI Demand, Economic Policy Hopes -- Market Talk
